Product Name:
RUNX1-pS276
Product Number:
ab-pn778
Target Full Name: Runt-related transcription factor 1
Target Alias: Acute myeloid leukemia 1 protein; Aml1 oncogene; AMLCR1; CBFA2; CBF-alpha 2; Core-binding factor subunit alpha-2; Core-binding factor, alpha 2 subunit; Oncogene AML-1; PEA2-alpha B; PEBP2A2; PEBP2-alpha B; Polyomavirus enhancer binding protein 2 alpha B subunit; Polyomavirus enhancer-binding protein 2 alpha B subunit; RUN1; RUNX1; SL3/AKV core-binding factor alpha B subunit; SL3-3 enhancer factor 1 alpha B subunit
Product Type Specific: RUNX1 (AML1) phosphosite-specific antibody
Antibody Code: PN778
Antibody Target Type: Phosphosite-specific
Antibody Phosphosite: S276
Protein UniProt: Q01196
Protein SigNET: AML1
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Antibody Immunogen Source: Synthetic phosphopeptide patterned after human RUNX1
Antibody Immunogen Sequence: TPI(pS)PGRAC
Antibody Immunogen Description: Corresponds to amino acid residues T273 to A280. S276 phosphorylation induces transcription and interaction with HDAC1 and SIN3A. This is the major site of in vivo phosphorylation of RUNX1 (AML1) based on ≥76 mass spectrometry reports recorded in PhosphoSitePlus. RUNX1 is known to be phosphorylated at this site in vitro by CDK1 (CDC2), CDK2, CDK6, ERK1 (MAPK3), ERK2 (MAPK1), and HIPK2.
Production Method: The immunizing peptide was produced by solid phase synthesis on a multipep peptide synthesizer and purified by reverse-phase hplc chromatography. Purity was assessed by analytical hplc and the amino acid sequence confirmed by mass spectrometry analysis. This peptide was coupled to KLH prior to immunization into rabbits. New Zealand White rabbits were subcutaneously injected with KLH-coupled immunizing peptide every 4 weeks for 4 months. The sera from these animals was applied onto an agarose column to which the immunogen peptide was thio-linked. Antibody was eluted from the column with 0.1 M glycine, pH 2.5. Subsequently, the antibody solution was neutralized to pH 7.0 with saturated Tris.
Antibody Modification: Unconjugated. Contact KInexus if you are interest in having the antibody biotinylated or coupled with fluorescent dyes.
Antibody Concentration: 0.75 mg/ml
Storage Buffer: Phosphate buffered saline pH 7.4, 0.05% Thimerasol
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Antibody microarray
Antibody Dilution Recommended: 2 µg/ml for immunoblotting
Antibody Species Reactivity: This antibody detects the target phosphoprotein in the following species due to conservation of amino acid sequence: Human | Chimpanzee | Rhesus macaque | Dog | Rat | Mouse | Zebra fish.
Related Product 1: AML2 T231 phosphorylation antibody (Cat. No.: AB-PN569)
Related Product 2: AML1 T273 phosphorylation antibody (Cat. No.: AB-PN568)
Scientific Background: RUNX1 (Runt-related transcription factor 1; AML1) is a critical transcription factor protein that regulates gene expression for hematopoietic stem cell differentiation into mature blood cells. It forms the heterodimeric complex core-binding factor (CBF) with CBFB, which stabilizes it and enhances its DNA-binding capacity. The CBF complex, binds to DNA to regulate hematopoiesis. It is important for establishing definitive hematopoiesis (blood cell formation) and immune system development. Beyond blood formation, it functions in nerve development (specifically pain sensing) and has roles in inflammatory responses, including the pathway. RUNX members modulate the transcription of their target genes through recognizing the core consensus binding sequence 5'-TGTGGT-3', or very rarely, 5'-TGCGGT-3', within their regulatory regions via their runt domain, while CBFB is a non-DNA-binding regulatory subunit that allosterically enhances the sequence-specific DNA-binding capacity of RUNX. The heterodimer complex bind to the core site of a number of enhancers and promoters, including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers, LCK, IL3 and GM-CSF promoters. It is essential for the development of normal hematopoiesis. It acts synergistically with ELF4 to transactivate the IL-3 promoter and with ELF2 to transactivate the BLK promoter. It inhibits KAT6B-dependent transcriptional activation. It is involved in lineage commitment of immature T cell precursors. CBF complexes repress ZBTB7B transcription factor during cytotoxic (CD8+) T cell development. They bind to RUNX-binding sequence within the ZBTB7B locus acting as transcriptional silencer and allowing for cytotoxic T cell differentiation. CBF complexes binding to the transcriptional silencer is essential for recruitment of nuclear protein complexes that catalyze epigenetic modifications to establish epigenetic ZBTB7B silencing. It controls the anergy and suppressive function of regulatory T-cells (Treg) by associating with FOXP3. It is expressed in all tissues examined except brain and heart, with highest levels in thymus, bone marrow and peripheral blood. Mutations and chromosomal translocations involving RUNX1 (like t (8;21)) are frequently observed in hematological malignancies, including acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplastic syndrome. It acts as a tumour suppressor in normal cells. This description may include information annotated by UniProt and/or Google AI.